Anti-obesity drug benefits 'no longer outweigh risks'

Acomplia's European marketing authorisation for obese and overweight people has been suspended by the European Medicines Agency (EMEA).

The EMEA said it has decided that the benefits of rimonabant, which is marketed in Europe as Acomplia, no longer outweigh its risks. Prescribers should not issue any prescriptions for Acomplia and should review the treatment of patients currently taking the medicine, the EMEA said.

There is no need for patients to stop treatment with Acomplia immediately, but patients who wish to stop can do so at any time, the EMEA advised. Patients who are currently taking Acomplia should consult their doctor or pharmacist at a convenient time to discuss their treatment.

Acomplia's manufacturer Sanofi-Aventis said that it was complying with the EMEA’s recommendation.

‘Sanofi-Aventis is committed to provide additional evidence for the re-evaluation of the benefit/risk profile of Acomplia in patients with diabetes and cardiovascular disease through the ongoing clinical studies,’ the company said in a statement.

‘Sanofi-Aventis remains committed to Acomplia to bring an important therapeutic approach to obese and overweight patients.’

The EMEA said it had assessed the benefits and risks of Acomplia, including data from studies completed since the drug was licensed. These showed an increased risk of psychiatric disorders patients taking Acomplia.

The EMEA said it believed that these side effects could not be adequately addressed by risk minimisation measures.

In addition, the agency said that the effectiveness of Acomplia in clinical practice had been found to be more limited than was expected on the basis of the clinical trials because available data indicate that patients generally take Acomplia
only for a short period.

tom.moberly@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

£20 notes spread out

VAT trap for PCNs could strip millions of pounds from general practice

Tens of millions of pounds could be stripped from general practice because work carried...

Talking General Practice logo

Podcast: Is the BMA representing GPs effectively, why GPs face a pension tax hit, and views on the workload crisis

In our regular news review the team discusses representation of GPs, a new survey...

Man sleeping

NICE guidance on insomnia backs app to replace sleeping pills

Hundreds of thousands of people with insomnia could be offered treatment via a mobile...

Health worker prepares a dose of COVID-19 vaccine

JCVI backs autumn COVID-19 booster campaign for high-risk adults and NHS staff

Frontline health and social care staff and adults at increased risk of severe illness...

GP consultation

Government accused of 'misleading' claims on general practice workforce

GP leaders have accused the government of making misleading claims about the general...

Consulting room door

LMC calls for enhanced access to be scrapped after abuse forces practice to close reception

A Midlands LMC has backed a practice forced to close its reception desk after abuse...